CAPROCK Group Inc. Trims Holdings in Illumina, Inc. (ILMN)

CAPROCK Group Inc. reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 38.7% during the third quarter, Holdings Channel reports. The fund owned 939 shares of the life sciences company’s stock after selling 594 shares during the quarter. CAPROCK Group Inc.’s holdings in Illumina were worth $345,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jennison Associates LLC grew its stake in shares of Illumina by 4.5% in the 2nd quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock worth $1,200,271,000 after buying an additional 185,745 shares in the last quarter. Fred Alger Management Inc. grew its stake in shares of Illumina by 21.4% in the 2nd quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock worth $217,413,000 after buying an additional 137,302 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Illumina by 5.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 604,615 shares of the life sciences company’s stock worth $168,863,000 after buying an additional 31,985 shares in the last quarter. Millennium Management LLC grew its stake in shares of Illumina by 219.8% in the 2nd quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock worth $153,318,000 after buying an additional 377,283 shares in the last quarter. Finally, Federated Investors Inc. PA grew its stake in shares of Illumina by 4.1% in the 2nd quarter. Federated Investors Inc. PA now owns 512,611 shares of the life sciences company’s stock worth $143,167,000 after buying an additional 20,324 shares in the last quarter. Institutional investors own 89.84% of the company’s stock.

A number of brokerages have commented on ILMN. Zacks Investment Research cut shares of Illumina from a “hold” rating to a “sell” rating in a research note on Tuesday. BidaskClub cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday. Deutsche Bank lifted their price objective on shares of Illumina to $350.00 and gave the stock a “buy” rating in a research note on Friday, October 12th. ValuEngine cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. Finally, UBS Group began coverage on shares of Illumina in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $340.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating and fifteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $324.76.

ILMN stock opened at $328.96 on Thursday. Illumina, Inc. has a 12 month low of $198.21 and a 12 month high of $372.61. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.74 and a quick ratio of 2.44. The stock has a market cap of $53.96 billion, a P/E ratio of 82.24, a PEG ratio of 3.04 and a beta of 0.97.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, July 30th. The life sciences company reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.32. Illumina had a net margin of 20.88% and a return on equity of 26.64%. The firm had revenue of $830.00 million during the quarter, compared to analysts’ expectations of $786.88 million. During the same period in the previous year, the company earned $0.82 EPS. The firm’s revenue for the quarter was up 25.4% compared to the same quarter last year. As a group, research analysts expect that Illumina, Inc. will post 5.46 earnings per share for the current year.

In related news, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction dated Wednesday, October 10th. The shares were sold at an average price of $321.58, for a total transaction of $1,061,214.00. Following the completion of the transaction, the director now directly owns 385,604 shares of the company’s stock, valued at approximately $124,002,534.32. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction dated Wednesday, October 10th. The stock was sold at an average price of $311.84, for a total transaction of $3,118,400.00. Following the transaction, the senior vice president now directly owns 80,805 shares of the company’s stock, valued at $25,198,231.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 52,483 shares of company stock valued at $17,702,063. 0.54% of the stock is owned by corporate insiders.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Read More: How is the S&P 500 index different from the DJIA?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply